Astec Lifesciences has informed that the Board of Directors of the Company (the Board), at its Meeting held today, on Tuesday, 24th June, 2025, has considered and approved the issue of fully paid-up Equity Shares of the Company of face value of Rs 10 each (the Equity Shares) for an amount not exceeding Rs. 250 Crore (Rupees Two Hundred and Fifty Crore) by way of a Rights Issue to the eligible Equity Shareholders of the Company as on the record date (to be determined and notified subsequently, and such issue, the Rights Issue), in accordance with applicable laws, including the Companies Act, 2013, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the SEBI ICDR Regulations), as amended, subject to such regulatory and statutory approvals, as may be relevant under the applicable laws. For the purposes of giving effect to the Rights Issue, the specific and detailed terms in relation to the Rights Issue, including but not limited to, the determination of the issue price, rights entitlement ratio, record date, timing of the rights issue and terms of payment will be determined by the Board and / or a duly constituted Committee of the Board of Directors authorized in this regard. The Meeting of the Board commenced at 10.00 a.m. and concluded at 11.25 am. This disclosure is made in terms of Regulation 30 read with Schedule III and other applicable provisions of the Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, as amended/updated from time to time.

The above information is a part of company’s filings submitted to BSE.